EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (10)
2022
2021
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2014
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647
2013
-
SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013
Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1011-1017
2012
-
Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
Journal of Clinical Oncology, Vol. 30, Núm. 13, pp. 1484-1491
-
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone
Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740
2010
-
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet, Vol. 375, Núm. 9712, pp. 377-384
2006
-
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902